145 related articles for article (PubMed ID: 25172328)
1. Myoglobin expression in prostate cancer is correlated to androgen receptor expression and markers of tumor hypoxia.
Meller S; Bicker A; Montani M; Ikenberg K; Rostamzadeh B; Sailer V; Wild P; Dietrich D; Uhl B; Sulser T; Moch H; Gorr TA; Stephan C; Jung K; Hankeln T; Kristiansen G
Virchows Arch; 2014 Oct; 465(4):419-27. PubMed ID: 25172328
[TBL] [Abstract][Full Text] [Related]
2. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer.
Boddy JL; Fox SB; Han C; Campo L; Turley H; Kanga S; Malone PR; Harris AL
Clin Cancer Res; 2005 Nov; 11(21):7658-63. PubMed ID: 16278385
[TBL] [Abstract][Full Text] [Related]
3. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia.
Banham AH; Boddy J; Launchbury R; Han C; Turley H; Malone PR; Harris AL; Fox SB
Prostate; 2007 Jul; 67(10):1091-8. PubMed ID: 17477366
[TBL] [Abstract][Full Text] [Related]
4. Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype.
Kristiansen G; Rose M; Geisler C; Fritzsche FR; Gerhardt J; Lüke C; Ladhoff AM; Knüchel R; Dietel M; Moch H; Varga Z; Theurillat JP; Gorr TA; Dahl E
Br J Cancer; 2010 Jun; 102(12):1736-45. PubMed ID: 20531416
[TBL] [Abstract][Full Text] [Related]
5. The Distinct Gene Regulatory Network of Myoglobin in Prostate and Breast Cancer.
Bicker A; Brahmer AM; Meller S; Kristiansen G; Gorr TA; Hankeln T
PLoS One; 2015; 10(11):e0142662. PubMed ID: 26559958
[TBL] [Abstract][Full Text] [Related]
6. Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer.
Goltz D; Montani M; Braun M; Perner S; Wernert N; Jung K; Dietel M; Stephan C; Kristiansen G
Pathology; 2015 Dec; 47(7):629-36. PubMed ID: 26517642
[TBL] [Abstract][Full Text] [Related]
7. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes.
Mori R; Dorff TB; Xiong S; Tarabolous CJ; Ye W; Groshen S; Danenberg KD; Danenberg PV; Pinski JK
Prostate; 2010 Nov; 70(15):1692-700. PubMed ID: 20564320
[TBL] [Abstract][Full Text] [Related]
8. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.
Guo Z; Yang X; Sun F; Jiang R; Linn DE; Chen H; Chen H; Kong X; Melamed J; Tepper CG; Kung HJ; Brodie AM; Edwards J; Qiu Y
Cancer Res; 2009 Mar; 69(6):2305-13. PubMed ID: 19244107
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
[TBL] [Abstract][Full Text] [Related]
10. Endogenous myoglobin in breast cancer is hypoxia-inducible by alternative transcription and functions to impair mitochondrial activity: a role in tumor suppression?
Kristiansen G; Hu J; Wichmann D; Stiehl DP; Rose M; Gerhardt J; Bohnert A; ten Haaf A; Moch H; Raleigh J; Varia MA; Subarsky P; Scandurra FM; Gnaiger E; Gleixner E; Bicker A; Gassmann M; Hankeln T; Dahl E; Gorr TA
J Biol Chem; 2011 Dec; 286(50):43417-28. PubMed ID: 21930697
[TBL] [Abstract][Full Text] [Related]
11. Independence of HIF1a and androgen signaling pathways in prostate cancer.
Tran MGB; Bibby BAS; Yang L; Lo F; Warren AY; Shukla D; Osborne M; Hadfield J; Carroll T; Stark R; Scott H; Ramos-Montoya A; Massie C; Maxwell P; West CML; Mills IG; Neal DE
BMC Cancer; 2020 May; 20(1):469. PubMed ID: 32450824
[TBL] [Abstract][Full Text] [Related]
12. Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants.
Jernberg E; Thysell E; Bovinder Ylitalo E; Rudolfsson S; Crnalic S; Widmark A; Bergh A; Wikström P
PLoS One; 2013; 8(11):e77407. PubMed ID: 24244276
[TBL] [Abstract][Full Text] [Related]
13. Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome.
Callen DF; Ricciardelli C; Butler M; Stapleton A; Stahl J; Kench JG; Horsfall DJ; Tilley WD; Schulz R; Nesland JM; Neilsen PM; Kumar R; Holm R
Oncol Rep; 2010 Apr; 23(4):1045-52. PubMed ID: 20204290
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia increases androgen receptor activity in prostate cancer cells.
Park SY; Kim YJ; Gao AC; Mohler JL; Onate SA; Hidalgo AA; Ip C; Park EM; Yoon SY; Park YM
Cancer Res; 2006 May; 66(10):5121-9. PubMed ID: 16707435
[TBL] [Abstract][Full Text] [Related]
15. Differential CARM1 expression in prostate and colorectal cancers.
Kim YR; Lee BK; Park RY; Nguyen NT; Bae JA; Kwon DD; Jung C
BMC Cancer; 2010 May; 10():197. PubMed ID: 20462455
[TBL] [Abstract][Full Text] [Related]
16. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients.
Noordzij MA; Bogdanowicz JF; van Krimpen C; van der Kwast TH; van Steenbrugge GJ
J Urol; 1997 Nov; 158(5):1880-4; discussion 1884-5. PubMed ID: 9334622
[TBL] [Abstract][Full Text] [Related]
18. Increased nuclear factor I/B expression in prostate cancer correlates with AR expression.
Nanda JS; Awadallah WN; Kohrt SE; Popovics P; Cates JMM; Mirosevich J; Clark PE; Giannico GA; Grabowska MM
Prostate; 2020 Sep; 80(13):1058-1070. PubMed ID: 32692871
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status.
Hong H; Kao C; Jeng MH; Eble JN; Koch MO; Gardner TA; Zhang S; Li L; Pan CX; Hu Z; MacLennan GT; Cheng L
Cancer; 2004 Jul; 101(1):83-9. PubMed ID: 15221992
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers.
Wang Y; Romigh T; He X; Tan MH; Orloff MS; Silverman RH; Heston WD; Eng C
Oncogene; 2011 Oct; 30(42):4327-38. PubMed ID: 21532617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
